Results 81 to 90 of about 80,532 (301)

Car-NK cell therapy for overcoming solid tumors

Highlights in Science, Engineering and Technology, 2023
There are many standard treatments for solid tumors, including surgery, chemotherapy, radiotherapy, or combination therapy, but all of them are difficult to maintain long-term anti-cancer effects. Recent immunotherapies such as Car-T have achieved remarkable results in hematologic cancers.
openaire   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Frontiers in Immunology
Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy targeting cancer cells via the generation of chimeric antigen receptors on NK cells which recognize specific cancer antigens. CAR-NK cell therapy is gaining attention
Jun Chang Kong, Mohammad Auwal Sa’ad, Mohammad Auwal Sa’ad, Hema Manusri Vijayan, Manickam Ravichandran, Manickam Ravichandran, Venugopal Balakrishnan, Seng Kong Tham, Gee Jun Tye   +8 more
doaj   +1 more source

Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies [PDF]

, 2009
Aim: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in human ...
Dian, Darius, Friese, Klaus, Janni, Wolfgang, Jeschke, Udo, Karsten, Uwe, Kuhn, Christina, Mayr, Doris, Mylonas, Ioannis   +7 more
core   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy

MedComm, 2023
Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft‐versus‐host disease and cytokine release syndrome, therapy resistance, limited ...
Yan Wang, Shengjie Jin, Qiqi Zhuang, Na Liu, Ruyi Chen, Sofia Abdulkadir Adam, Jie Jin, Jie Sun   +7 more
doaj   +1 more source

Crystal Structure of the C-type Lectin-like Domain from the Human Hematopoietic Cell Receptor CD69 [PDF]

, 2001
CD69, one of the earliest specific antigens acquired during lymphoid activation, acts as a signal-transducing receptor involved in cellular activation events, including proliferation and induction of specific genes.
Andrea S. Llera, Bajorath, Bates, Bléry, Borrego, Boyington, Braud, Brown, Brünger, Cebrián, Childs, Chothia, Cowtan, Day, De Maria, Drickamer, Drickamer, Drickamer, Esnouf, Fernando Viedma, Francisco Sánchez-Madrid, Garboczi, Gouet, Hamann, Hubbard, Hubbard, Jones, José Tormo, Kabsch, Lanier, Lanier, Laskowski, Laskowski, Lauzurica, Lee, Lo Conte, López-Botet, López-Botet, López-Cabrera, Marzio, Matsumoto, McDonald, Merrit, Nakamura, Navaza, Nicholls, Otwinowski, Read, Santis, Stuart, Studier, Suzuki, Sánchez-Mateos, Sánchez-Mateos, Testi, Testi, Testi, Tormo, Ugolini, Weis, Weis, Weis, Ziegler, Zingoni   +63 more
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment

Cells
CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells.
Tatiana Budagova, Anna Efremova, Margarita Maiak, Dmitry Goldshtein   +3 more
doaj   +1 more source

2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

Journal of Hematology & Oncology, 2019
Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated extraordinary efficacy in B cell malignancy therapy and have been approved by the US Food and Drug Administration for diffuse large B cell lymphoma and acute B lymphocytic ...
Yingxi Xu, Qian Liu, Mengjun Zhong, Zhenzhen Wang, Zhaoqi Chen, Yu Zhang, Haiyan Xing, Zheng Tian, Kejing Tang, Xiaolong Liao, Qing Rao, Min Wang, Jianxiang Wang   +12 more
doaj   +1 more source